News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Spectrum Pharmaceuticals, Inc. (SPPI) Announces Extension of FUSILEVĀ® (levoleucovorin) for Injection Patent Until 2022


1/17/2013 9:25:44 AM

HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the United States Patent and Trademark Office (USPTO) has extended by more than two years U.S. Patent No. 6,500,829, which covers FUSILEVĀ® (levoleucovorin) for injection. The extension was granted through the Hatch-Waxman Act and extends the original December 31, 2019 expiration date to March 7, 2022.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES